Amicus Therapeutics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Amicus Therapeutics Bundle
See the Bigger Picture
Curious where Amicus Therapeutics’ portfolio lands on the BCG Matrix? This snapshot shows market momentum and product risk, but the full BCG Matrix lays out each asset’s quadrant, cash flow implications, and tactical moves you can act on now. Purchase the complete report for quadrant-by-quadrant analysis, strategic recommendations, and downloadable Word and Excel files that make board-ready presentations quick and painless.
Stars
Pombiliti + Opfolda (Pompe launch)
Newly approved combo Pombiliti + Opfolda enters a growing Pompe market in 2024 with meaningful clinical differentiation driving rapid uptake and early switches from legacy ERTs. Leadership is contestable; early momentum will determine pricing and share. Expect heavy near-term cash burn for access, centers-of-excellence, and switching programs. Continue investing to cement share and transition toward a future Cash Cow.
Galafold growth segments (Fabry, oral-first)
In the oral-therapy niche for Fabry, adoption is expanding as diagnostics and switches increase, with Galafold reported 2024 revenue near $271 million and growing double digits year-over-year. Strong brand equity and patient preference can push share higher in these growth pockets, but converting non-amenable patients needs steady promotion and real-world evidence. Stay aggressive on access and prescriber education to keep the uptake curve rising.
Global rare-disease commercial engine
Amicus's hard-won field team, patient services and center relationships create a durable advantage in a rare-disease landscape that includes over 7,000 known conditions affecting roughly 300 million people worldwide as of 2024. As new indications and geographies open, this commercial engine scales but requires ongoing investment in talent, training and data. The payoff: faster launch velocity and greater share capture in expanding markets.
Real‑world evidence and label-expansion pathways
Generating real-world outcomes in Fabry (prevalence ~1:40,000–1:117,000) and Pompe (prevalence ~1:40,000) markets accelerates growth and de-risks payer and clinician adoption; robust RWE increases confidence for switches and new starts. It requires significant investment but compounds competitive advantage as label-expansion and uptake scale.
- Fabry prevalence: ~1:40,000–1:117,000
- Pompe prevalence: ~1:40,000
- RWE: high upfront cost, long-term defensive value
Diagnostic and patient-finding programs
Diagnostic and patient-finding programs are Stars for Amicus in 2024: more diagnosed patients directly expand eligible treatment starts as markets rise, and screening partnerships plus genetics workflows are still scaling across regions. These programs require upfront budget but convert directly into market share and sustainable growth. Focus investment where prevalence remains under-identified to unlock pipeline value.
2024 Pompe launch; ~271M Fabry revenue — invest diagnostics & RWE
New Pombiliti+Opfolda launched 2024 into a growing Pompe market (~1:40,000) with rapid uptake potential but high near-term cash burn for access; Galafold reported ~271 million 2024 revenue with double-digit growth in Fabry (~1:40,000–1:117,000). Invest in diagnostics, RWE and field teams to convert diagnosis → starts and cement Star positions toward future Cash Cows.
| Metric | 2024 |
|---|---|
| Pombiliti+Opfolda | Launched 2024 |
| Galafold revenue | ~271 million |
| Pompe prevalence | ~1:40,000 |
| Fabry prevalence | ~1:40,000–1:117,000 |
What is included in the product
Detailed Word Document
BCG Matrix review of Amicus: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Amicus Therapeutics — clarifies portfolio focus, eases stakeholder decisions and speeds executive buy-in.
Cash Cows
Galafold base business (mature markets)
Galafold in mature markets delivers dependable cash from recurring refills and an established prescriber base, supporting Amicus net product revenue of over $300 million in 2023. Stable reimbursement and durable access minimize sales volatility while growth is moderate rather than hyper. Promotion can be efficient and targeted to specialist channels, allowing management to milk margins and reinvest in high-touch patient support to preserve adherence and outcomes.
Established Fabry centers and loyal prescribers
Established Fabry centers and loyal prescribers give Amicus predictable demand and lower cost-to-serve, with Galafold remaining a core revenue driver in 2024. Competitive risk is manageable with light-touch engagement focused on retention rather than expansion. Optimize call frequency to maintain uptake and satisfaction, not to increase field costs. Harvest cash from this cash cow to fund high-growth R&D and launches.
Supply chain and manufacturing efficiencies
Scale and learning effects in steady-volume markets drive down Amicus Therapeutics' COGS, with industry 2024 benchmarks showing manufacturing upgrades can lift gross margins by roughly 5–8%. Targeted capital upgrades pay back through higher gross margin and throughput, making these low-glamour moves high-ROI for a cash-cow portfolio. Continuous tightening of supply-chain processes frees incremental cash for reinvestment or shareholder returns.
Long-term adherence and patient support
Long-term adherence and patient support at Amicus smooth revenue by keeping patients on therapy; 2024 industry data show adherence programs can raise persistence by about 10–20%, making incremental spend small versus lifetime value of rare-disease patients. Focus remains on simple, high-impact services (nurse support, copay assistance, reminders), keeping this a reliable cash generator with minimal growth investment.
- Retention programs: steady revenue
- Incremental spend: low vs lifetime value
- Services: nurse support, copay, reminders
- 2024 impact: adherence +10–20%
Geographies with stable access
Geographies with settled pricing and reimbursement (US, EU5, Japan) deliver predictable cash inflows for Amicus’s approved therapies, reducing volatility and commercial noise. Upside is limited; focus should be on maintaining compliance, uninterrupted supply and avoiding incremental promotional spend. Bank the cash to fund pipeline milestones and protect runways.
- Stable markets: US, EU5, Japan
- Priority: compliance & supply continuity
- Strategy: limit promo spend, allocate cash to R&D/benchmarks
>$300M net•adherence +10-20%•margin+5-8%
Galafold supplies steady cash with Amicus net product revenue >$300M in 2023, stable reimbursement in US/EU5/Japan and low sales volatility. Efficient specialist promotion and patient-support programs (adherence +10–20% in 2024 benchmarks) keep incremental spend low while preserving lifetime value. Manufacturing/supply upgrades can boost gross margins ~5–8%, freeing cash to fund R&D and launches.
| Metric | Value |
|---|---|
| Net product revenue (2023) | >$300M |
| Key markets | US, EU5, Japan |
| Adherence impact (2024) | +10–20% |
| Gross margin upside | +5–8% |
Delivered as Shown
Amicus Therapeutics BCG Matrix
The file you're previewing is the exact Amicus Therapeutics BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just a fully formatted, analysis-ready document designed for strategic clarity. Once bought, the full file is immediately downloadable and editable. Use it in presentations, planning sessions, or client deliverables without extra tweaks.
Dogs
Non-core early discovery threads
Non-core early discovery threads at Amicus are small projects that do not ladder to the core genetic/lysosomal thesis and lack clear development paths; they absorb attention and budget with minimal progress. These initiatives divert resources from priority programs and historically show low turnaround probability. Recommended action: trim or exit to protect capital and focus on core pipeline execution.
Micro-markets with chronic reimbursement friction
Micro-markets here target orphan populations (eg, Fabry disease prevalence ~1 in 40,000–1 in 117,000), yielding patient pools in the low hundreds per country; heavy prior-authorization and specialty pharmacy admin create persistent reimbursement friction and low real-world access. Cash and commercial effort get tied up for negligible market share, the structural payor hurdles are hard to fix, so de-prioritize internally or seek out-license/partnering to externalize execution risk.
Legacy platform experiments without differentiation
Legacy platform experiments without a clear clinical edge or operational moat rarely drive value for Amicus (ticker FOLD); by 2024 market sentiment placed the company sub-$2B market cap, indicating limited investor reward for undifferentiated assets.
Such programs tend to break even at best, often producing single-digit ROI or marginal net benefit while consuming R&D and SG&A resources.
Stop the drip: reallocate annual spend and headcount from these platforms to programs with demonstrable clinical pull and higher projected IRR to maximize shareholder value.
One-off regional pilots that never scaled
One-off regional pilots for Amicus showed high upfront setup costs (typical pilot programs range $0.8–1.5M in similar rare-disease launches in 2024), low repeatability and minimal prescriptions, so unit economics and the math don’t land versus scalable channels; sunsetting these pilots reduces operational complexity and cash drag while preserving data and HCP learnings.
- cost: high setup, low ROI
- scale: low repeatability
- prescriptions: minimal uptake
- action: sunset pilots, retain learnings
Standalone capabilities duplicated elsewhere
Standalone capabilities duplicated elsewhere—manufacturing, basic clinical ops, or commercial support—are provided more efficiently by larger partners or CDMOs, adding fixed overhead to Amicus with little strategic upside in low-growth lysosomal disease niches; these functions are hard to justify and drain margins, so outsourcing or winding down is the prudent choice.
De-prioritize dog programs: low-growth, single-digit ROI draining R&D and SG&A
Dogs are non-core, low-growth projects draining R&D and SG&A with single-digit ROI; de-prioritize, out-license, or sunset to protect capital. Micro-market access (eg Fabry 1/40,000–1/117,000) and heavy payor friction limit scale. 2024 market sentiment valued Amicus under $2B, supporting focus on core programs.
| Metric | Value | 2024 |
|---|---|---|
| Market cap | <$2B | 2024 |
| Fabry prevalence | 1/40,000–1/117,000 | 2024 |
| Pilot cost | $0.8–1.5M | 2024 |
| Typical ROI | Single-digit | 2024 |
Question Marks
Next-wave Pompe indications/labels
Next-wave Pompe indications/labels (extensions, sub-populations, earlier-line use) can unlock substantial growth but begin from a tiny patient base—Pompe incidence ~1 in 40,000 births. Heavy lift remains: Phase 2/3 trials, payer access and clinician education with typical pivotal timelines ~2–4 years. Positive pivotal data could flip the asset to a Star. Fund quickly to clear proof points and accelerate uptake.
Lysosomal gene therapy partnerships
Platform potential for lysosomal gene therapy is real given over 50 distinct lysosomal storage disorders affecting collectively about 1 in 7,000 live births, and the market is intensely competitive. Amicus’ share position remains nascent with programs capital intensive and timelines highly uncertain. If early clinical or biomarker signals in 2024 are strong, lean in; if not, cut clean—trajectory is binary toward Star or exit.
Asia expansion for Fabry/Pompe
Asia represents ~4.7 billion people (UN 2024), offering high-growth patient pools for Fabry and Pompe despite Amicus holding low current share in the region. Success requires local access wins, expanded diagnostics and KOL networks to drive identification and uptake. Initial roll-out will be cash hungry given testing, distribution and education costs. Prioritize a few anchor countries to prove traction and scale evidence-based access.
New diagnostic collaborations
New diagnostic collaborations with screening tech and genomics partners can accelerate patient-finding; with ~350 million rare-disease patients globally and exome diagnostic yields around 30% (2024), upfront costs rise while revenue lags. If conversion from ID to treated patient improves, the model shifts to a growth flywheel. Pilot, measure key metrics (cost per identified patient, conversion rate), then scale or stop.
- Metric: cost per identified patient
- Target: conversion rate ≥15–25% to justify scale
- Bench: exome yield ~30% (2024)
- Action: 3–6 month pilot, KPI gating
Lifecycle innovations (formulation, delivery)
Lifecycle innovations in formulation or delivery for Amicus Therapeutics are question marks: improved convenience or administration (oral/less frequent dosing) can quickly grow market share from a low base but requires R&D spend and payer alignment. Payoff is outsized if adherence improves materially; industry studies show simplified regimens can raise adherence by double digits. Treat as time-bound bets with predefined development and commercial gates.
- R&D investment required
- Payer alignment crucial
- Adherence gains can be double-digit
- Set clear go/no-go gates and timelines
Pompe 1:40,000; Lysosomal 1:7,000; Asia 4.7B; Exome yield ~30%
Pompe label expansions target a tiny base (~1:40,000 births) but could become a Star with positive pivots in 2–4 years; fund to clear proof points. Lysosomal gene therapy covers ~1:7,000 births collectively; early 2024 signals are binary—invest on strong biomarkers, exit on weak. Asia (~4.7B, UN 2024) and diagnostics (exome yield ~30% in 2024) are high-leverage but cash-intensive; pilot 3–6 months with 15–25% conversion gate.
| Metric | Value |
|---|---|
| Pompe incidence | 1:40,000 |
| Lysosomal burden | 1:7,000 |
| Asia pop | 4.7B (UN 2024) |
| Exome yield | ~30% (2024) |
| Conversion target | 15–25% |